Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Swiss Cancer Institute: Clinical Trials & FDA Approval Profile

Swiss Cancer Institute (Global / Institutional) sponsors 25 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (10 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)24.0%
Median Closed Enrollment vs National (145 pts)43 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Swiss Cancer Institute
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)25
Active Pipeline (Recruiting Now)16 (10)
Completed vs Stopped Early3 / 6 (24.0%)
Median Closed Actual Enrollment43 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Swiss Cancer Institute
Hospital Research SiteLocationShared Protocols
Kantonsspital St. GallenSankt Gallen16

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Swiss Cancer Institute
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06401980Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase IIRECRUITING
NCT07020065Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With MetastPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Swiss Cancer Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI